210
Participants
Start Date
March 31, 2011
Primary Completion Date
February 28, 2013
Study Completion Date
May 31, 2013
etanercept
Administered by subcutaneous injection once weekly.
Placebo
Placebo subcutaneous injection
DMARD Therapy
Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
Research Site, Erie
Research Site, Frederick
Research Site, Chesapeake
Research Site, Greer
Research Site, Atlanta
Research Site, Jacksonville
Research Site, Tampa
Research Site, Sebring
Research Site, Sarasota
Research Site, Ocala
Research Site, Birmingham
Research Site, Tuscaloosa
Research Site, Lexington
Research Site, Mayfield Village
Research Site, Akron
Research Site, Saint Clair Shores
Research Site, Lansing
Research Site, Bismarck
Research Site, Springfield
Research Site, Oklahoma City
Research Site, Oklahoma City
Research Site, Dallas
Research Site, San Antonio
Research Site, Denver
Research Site, Meridian
Research Site, Scottsdale
Research Site, Peoria
Research Site, Inglewood
Research Site, Encino
Research Site, Upland
Research Site, La Jolla
Research Site, Victorville
Research Site, Hemet
Research Site, Murrieta
Research Site, Tustin
Research Site, Santa Maria
Research Site, Portland
Research Site, Seattle
Research Site, Winnipeg
Research Site, St. John's
Research Site, Burlington
Research Site, Laval
Research Site, Montreal
Research Site, Montreal
Research Site, Montreal
Research Site, Québec
Research Site, Saint-Eustache
Lead Sponsor
Amgen
INDUSTRY